An Open-label Phase 1 of Pembrolizumab in Combination With Bevacizumab and Pegylated Liposomal Doxorubicin in Patients With Platinum Resistant Epithelial Ovarian Cancer

Trial ID # NCT03596281; PEMBOV
Phase I
Drug Class Immunotherapy: Checkpoint Inhibitors/PD-1
Drug Name Pembrolizumab
Alternate Drug Names Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475
Drugs in Trial Liposomal doxorubicin, Pembrolizumab, Bevacizumab
Eligible Participant

Platinum resistant or refractory ovarian cancer

Patients Enrolled

Bev+Pem: 19 patients, Bev+PLD+Pem: 22 patients, median 3 prior therapies (1-13), 41% primary Pt-R, 82% w/ prior Bev, 41% w/ prior PARPi

Therapy Setting


Study Design

Open-Label, Non-randomized


CBR, ORR, DCR, PFS, evaluated per RECIST


ORR: 26.3% (1CR, 4PR, n=19) (not dependent on prior Bev therapy)
DCR: 78.9%
PFS: 4.7 months

ORR: 31.6% (6PR, n=19)
DCR: 78.9% (6PR, 8SD, n=19)
CBR: 53%
PFS: 4.8 months


Pembrolizumab+bevacizumab with or without liposomal doxorubicin is well tolerated and demonstrate durable responses in platinum resistant ovarian cancer patients


Michels J et al. Pembrolizumab and bevacizumab in platinum resistant epithelial ovarian cancer patients. SITC (2021) abstract 355

Michels J et al. PemBOv trial: Pembrolizumab plus bevacizumab with or without pegylated liposomal doxorubicin-based chemotherapy in patients with platinum-resistant ovarian cancer. J Clin Oncol 40, 2022 (suppl 16; abstr 5575)

Michels J et al. Poster

Contact Us
Contact Us

We are here to help! Send us a message below or give us a call at (858) 657-0282.